Device Trends To Watch In 2012

For much of the device industry, 2011 was marked by continuing change across the medtech ecosystem, most notably in the economy, the regulatory process, and the financing/innovation model. For 2012, we predict more of the same: the only certainty is continuing uncertainty.

Songwriter Tom Petty observed that “The waiting is the hardest part.” For those who have lived through the past few years in the medical device industry, Petty is truly preaching to the choir. The theme of last year’s annual review of the device industry was change; medtech was in a state of transition, almost as if waiting for the other shoe to drop, on a number of fronts. We optimistically suggested that 2011 would see one or more of those shoes finally fall, bringing some resolution, most notably in the regulatory area. (See Also see "Top Device Stories Of 2010: Waiting For The Other Shoes To Fall" - In Vivo, 1 January, 2011..) However, one year later, about the only thing we can comfortably predict is that the medical device industry is going to be living with uncertainty for the foreseeable future.

Perhaps the best example is the economy. While there is some reason for optimism concerning the state of the US economy, now the situation in Europe looks dire. This comes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.